Dorsey E,Sherer T,Okun MS,Bloem BR .2018 .The emerging evidence of the Parkinson pandemic. J Parkinsons Dis, 8(s1) : .
Vos T,Allen C,Arora M,Barber RM,Bhutta ZA,Brown A .2016 .The Lancet. , 388(10053) : 1545-602.
Lotharius J,Brundin P .2002 .Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein. Nat Rev Neurosci, 3(12) : 932-42.
Kouli A,Torsney KM,Kuan W .2018 .Parkinson's disease: etiology, neuropathology, and pathogenesis. Exon Publications, : 3-26.
Sivaraman D,Srikanth J .2016 .Discovery of novel monoamine oxidase-B inhibitors by molecular docking approach for Alzheimer's and Parkinson's disease Treatment. Int J Pharm Sci Rev Res, 40(1) : 245-50.
Westlund K,Denney R,Rose R,Abell C .1988 .Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neurosci, 25(2) : 439-56.
Edmondson D,Mattevi A,Binda C,Li M,Hubalek F .2004 .Structure and mechanism of monoamine oxidase. Curr Med Chem, 11(15) : 1983-93.
Nicotra A,Pierucci F,Parvez H,Senatori O .2004 .Monoamine oxidase expression during development and aging. Neurotoxicology, 25(1-2) : 155-65.
Dezsi L,Vecsei L .2017 .Monoamine oxidase B inhibitors in Parkinson's disease. CNS Neurol Disord Drug Targets, 16(4) : 425-39.
Lecht S,Haroutiunian S,Hoffman A,Lazarovici P .2007 .Rasagiline-a novel MAO B inhibitor in Parkinson's disease therapy. Ther Clin Risk Manag, 3(3) : 467-74.
Riederer P,Müller T. .2018 .Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: Clinical-pharmacological aspects. J Neural Transm, 125 : 1751-7.
Pinzi L,Rastelli G.,Molecular G. .2019 .Docking: Shifting Paradigms in Drug Discovery. Int J Mol Sci, 20(18) : 4331.
Sethi A,Joshi K,Sasikala K,Alvala M.,Gaitonde V,Karmakar P,Trivedi A . .Molecular docking in modern drug discovery: Principles and recent applications. United Kingdom: IntechOpen; 2019, : 21-47.
Kumar S,Pandey AK .2013 .Chemistry and biological activities of flavonoids: an overview. The Scientific World Journal, : .
Yanagihara N,Zhang H,Toyohira Y,Takahashi K,Ueno S,Tsutsui M .2014 .New insights into the pharmacological potential of plant flavonoids in the catecholamine system. Journal of Pharmacological Sciences, 124(2) : 123-8.
Han XH,Hong SS,Hwang JS,Lee MK,Hwang BY,Ro JS .2007 .Monoamine oxidase inhibitory components from Cayratia japonica. Arch Pharm Res, 30(1) : 13-7.
Kumar S,Ayyannan SR .2022 .Identification of new small molecule monoamine oxidase-B inhibitors through pharmacophore-based virtual screening, molecular docking and molecular dynamics simulation studies. J Biomol Struct Dyn, : 1-22.
Abdelgawad MA,Oh JM,Parambi DG,Kumar S,Musa A,Ghoneim MM .2022 .Development of bromo-and fluoro-based α, β-unsaturated ketones as highly potent MAO-B inhibitors for the treatment of Parkinson's disease. J Mol Struct, 1266 : 133545.
Soufi W,Merad M,Hacene FB,Ghalem S. . .Study of Monoamine Oxidase-B and Indole Derivatives Using Two Molecular Docking Programs: Molegro and MOE. , : .
Kong LD,Tan RX,Woo AY,Cheng CH .2001 .Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol, 88(2) : 75-80.
Booth NL,Overk CR,Yao P,Burdette JE,Nikolic D,Chen SN .2006 .The chemical and biologic profile of a red clover (Trifolium pratense L.) phase II clinical extract. J Altern Complement Med, 12(2) : 133-9.
Sharma K. Chromone .2022 .Scaffolds in the Treatment of Alzheimer's and Parkinson's Disease: An Overview. ChemistrySelect, 7(18) : .
Seong SH,Kim BR,Cho ML,Kim TS,Im S,Han S .2022 .Phytoestrogen Coumestrol Selectively Inhibits Monoamine Oxidase-A and Amyloid β Self-Aggregation. Nutrients, 14(18) : 3822.
Das T,Saha SC,Sunita K,Majumder M,Ghorai M,Mane AB .2022 .Promising botanical-derived monoamine oxidase (MAO) inhibitors: Pharmacological aspects and structure-activity studies. S Afr J Bot, 146 : 127-45.
Musa A,Della Grace Thomas Parambi MS,Alshammari RB,Abdelgawad MA,Sundar D,Panda MKS .2022 .In Silico Approaches to Naturally Existing Chalcones and Flavonoids on Mao Inhibitory Action: A Boon to CNS Drug Discovery. In: Flavonoids and Phenolics, : 173-95.
Mahnashi MH,Ayaz M,Ghufran M,Almazni IA,Alqahtani O,Alyami BA .2023 .Phytochemicals-based β-amyloid cleaving enzyme-1 and MAO-B inhibitors for the treatment of Alzheimer's disease: molecular simulations-based predictions. J Biomol Struct Dyn, : 1-13.
Liu LX,Chen WF,Xie JX,Wong MS .2008 .Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease. Neurosci Res, 60(2) : 156-61.
Irwin JJ,Sterling T,Mysinger MM,Bolstad ES,Coleman RG .2012 .ZINC: a free tool to discover chemistry for biology. J Chem Inf Model, 52(7) : 1757-68.
Biovia DS .2017 .Discovery studio modeling environment. Release, : .
Trott O,Olson AJ .2010 .AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem, 31(2) : 455-61.
DeLano WL .2002 .The PyMOL molecular graphics system. , : .
Daina A,Michielin O,Zoete V. .2017 .SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep, 7(1) : 42717.
Pires DE,Blundell TL,Ascher DB .2015 .pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem, 58(9) : 4066-72.
Walters WP .2012 .Going further than Lipinski's rule in drug design. Expert Opin Drug Discov, 7(2) : 99-107.
Saeed A,Rehman S,Channar PA,Larik FA,Abbas Q,Hassan M .2017 .Long chain 1-acyl3-arylthioureas as jack bean urease inhibitors, synthesis, kinetic mechanism and molecular docking studies. J Taiwan Inst Chem Eng, 77 : 54-63.
Hecht D,Fogel GB .2009 .Computational intelligence methods for ADMET prediction. Front Drug Des Discov, 4(27) : 351-77.
Hosea NA,Jones HM .2013 .Predicting pharmacokinetic profiles using in silico derived parameters. Mol Pharm, 10(4) : 1207-15.
Hardjono S,Siswandono S,Andayani R .2018 .Evaluation of N-benzoylthiourea derivatives as possible analgesic agents by predicting their physicochemical and pharmacokinetic properties, toxicity, and analgesic activity. Indones J Biotechnol, 22(2) : 76-85.
Hu YQ,Fan J,Song XF,Vitro In,‐ In .2018 .‐methylenetethered Isatin‐moxifloxacin Hybrids. J Heterocycl Chem, 55(1) : 246-50.
Xu Z,Song XF,Fan J,Lv ZS,‐ ZS .2018 .‐ methylene‐tethered (Thio) semicarbazoneisatin‐moxifloxacin Hybrids. J Heterocycl Chem, 55(1) : 77-82.
Drusano G,Standiford H,Plaisance K,Forrest A,Leslie J,Caldwell J .1986 .Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother, 30(3) : 444-6.
Moroy G,Martiny VY,Vayer P,Villoutreix BO,Miteva MA .2012 .Toward in silico structure-based ADMET prediction in drug discovery. Drug Discov Today, 17(1-2) : 44-55.